Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 12, 2014, Pages 1419-1424

  Caviglia, Gian Paolo ^a   Pantaleoni, Stefano ^b   Touscoz, Giovanni Antonio ^a   Adriani, Alessandro ^b   Rosso, Chiara ^a   Smedile, Antonina ^a   Pellicano, Rinaldo ^b   Astegiano, Marco ^b   Bresso, Francesca ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fecal calprotectin; Inflammatory bowel disease clinical; Irritable bowel syndrome

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN;

ADOLESCENT; ADULT; AGED; CHEMISTRY; CLINICAL TRIAL; COLONOSCOPY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FECES; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MALE; METABOLISM; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; COLONOSCOPY; DIAGNOSIS, DIFFERENTIAL; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84914173489     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2014.934913     Document Type: Article

References (22)

1. Berntzen HB, Fagerhol MK. L1, a major granulocyte protein: antigenic properties of its subunits. Scand J Clin Lab Invest 1988;48:647-52.
2. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009;58:859-68.
3. Burri E, Beglinger C. Faecal calprotectin in the diagnosis of inflammatory bowel disease. Biochem Med (Zagreb) 2011; 21:245-53.
4. Wildt S, Nordgaard Lassen I, Bendtsen F, Rumessen JJ. Metabolic and inflammatory faecal markers in collagenous colitis. Eur J Gastroenterol Hepatol 2007;19:567-74.
5. Shastri YM, Bergis D, Povse N, Schafer V, Shastri S, WeindelM, et al. Prospectivemulticenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008; 121:1099-106.
6. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjamason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenteroly 2005;128:1172-8.
7. Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-6.
8. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, NaessAndresenCF, et al.Functional and clinical aspects of the myelomonocyte protein calprotectin. J Clin Pathol 1997;50: 113-23.
9. Schoepfer AM, Trummler M, Seeholzer P, Seibold Schmid B, Seibold F. Discriminating IBD from IBS: comparison of test performance of fecalmarkers, blood leukocytes,CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-9.
10. Ton H, Brandsnes Dale S, Hotlund J, Skuibina F, Schjonsby H, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41-54.
11. Lee YJ, Park KS. Irritable bowel syndrome: Emerging paradigm in pathophysiology. World J Gastroenterol 2014;20: 2456-69.
12. D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, et al. Can Calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103: 2007-14.
13. Fiehn AM, Bjørnbak C, Warnecke M, Engel PJ, Munck LK. Observer variability in the histopathologic diagnosis of microscopic colitis and subgroups. Hum Pathol 2013;44:2461-6.
14. Talley NJ. Irritable bowel syndrome: definition, diagnosis, and epidemiology. Bailleres Best Pract Res Clin Gastroenterol 1999;13:371-84.
15. Licata A, Randazzo C, Cappello M, Calvaruso V, Butera G, Florena AM, et al. Fecal calprotectin in clinical practice. A noninvasive screening tool for patients with chronic diarrhea. J Clin Gastroenterol 2012;46:504-8.
16. Costa F,MumoloMG, BelliniM, RomanoMR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642-7.
17. Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol 2000;35:64-9.
18. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P,Tie A, et al.Activationof themucosal immunesysteminirritablebowel syndrome. Gastroenterology 2002;122:1778-83.
19. Cremon C, Gargano L, Morselli-Labate AM, Santini D, De Giorgio R, Stenghellini V, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392-400.
20. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923-9.
21. Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:1205-12.
22. Van Rheenen PF, Van de Vijer E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic mata-analysis. BMJ 2010;341: c3369.